Hepion Pharmaceuticals (NASDAQ:HEPA) Stock Price Down 1.4% – Should You Sell?

Hepion Pharmaceuticals, Inc. (NASDAQ:HEPA) shares fell 1.4% during mid-day trading on Friday . The stock traded as low as $0.60 and last traded at $0.65. 18,905 shares were traded during mid-day trading, a decline of 79% from the average session volume of 88,359 shares. The stock had previously closed at $0.66.

Hepion Pharmaceuticals Stock Performance

The company has a 50-day simple moving average of $0.70 and a 200-day simple moving average of $0.95. The stock has a market cap of $3.77 million, a P/E ratio of -0.10 and a beta of 1.84.

Hepion Pharmaceuticals (NASDAQ:HEPA) last issued its quarterly earnings data on Tuesday, August 13th. The company reported ($0.68) earnings per share (EPS) for the quarter.

Institutional Investors Weigh In On Hepion Pharmaceuticals

A hedge fund recently raised its stake in Hepion Pharmaceuticals stock. Armistice Capital LLC increased its stake in shares of Hepion Pharmaceuticals, Inc. (NASDAQ:HEPA) by 32.3% during the 2nd quarter, according to its most recent disclosure with the SEC. The institutional investor owned 516,000 shares of the company’s stock after acquiring an additional 126,000 shares during the period. Armistice Capital LLC owned about 9.43% of Hepion Pharmaceuticals worth $526,000 as of its most recent filing with the SEC. 17.24% of the stock is currently owned by hedge funds and other institutional investors.

About Hepion Pharmaceuticals

Hepion Pharmaceuticals, Inc, a biopharmaceutical company, focuses on the development of drug therapy treatment for chronic liver diseases in the United States. It develops Rencofilstat, a cyclophilin inhibitor that has completed Phase 2a clinical trials to target multiple pathologic pathways involved in the progression of liver disease; and is in phase 2 clinical development for the treatment of non-alcoholic steatohepatitis (NASH), as well as preclinical studies of Rencofilstat shows reduction in liver fibrosis, liver inflammation, liver tumor burden, and titers of HBV, HCV, HDV, and HIV-1, and has demonstrated antiviral activities for hepatitis B, C, and D viruses through several mechanisms.